证券代码：688302 证券简称：海创药业 公告编号：2025-056 海创药业股份有限公司 关于首次公开发行股票部分募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 海创药业股份有限公司（以下简称"公司"或"海创药业"）于 2025 年 12 月 24 日召开了第二届董事会第十六次会议，审议通过了《关于首次公开发行股 票部分募投项目延期的议案》，综合考虑当前首次公开发行股票部分募投项目的 实施进度等因素，同意公司将"研发生产基地建设项目"达到预定可使用状态日 期调整至 2026 年 12 月 31 日，保荐人中信证券股份有限公司（以下简称"保荐 人"）出具了无异议的核查意见，该事项无需提交公司股东会审议。现将相关情 况公告如下： 一、 募集资金基本情况 注：研发生产基地建设项目累计已投入募集资金金额大于拟投入募集资金金额，超出部 根据中国证券监督管理委员会于 2022 年 1 月 28 日印发的《关于同意海创药 业股份有限公司首次公开发行股票注册的批复》（证监许可﹝2022﹞250 号），并 经上海证券 ...

证券代码：688302 证券简称：海创药业 公告编号：2025-057 海创药业股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （二） 股东会召开的地点：四川省成都市高新区科园南路 5 号蓉药大厦 1 栋 4 层公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 90 | | --- | --- | | 普通股股东人数 | 90 | | 2、出席会议的股东所持有的表决权数量 | 32,256,383 | | 普通股股东所持有表决权数量 | 32,256,383 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 32.5770 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 32.5770 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 本次股东会由董事会召集，董事长 YUANWEI CHEN（ ...

中国成都市高新区天府一街 535 号两江国际 B 栋 33 层 610000 33/F, Building B, Twin Rivers International, No.535 Tianfu 1st Street, High‐tech District, Chengdu 610000, China 电话 Tel: +86 28 6753 5588 传真 Fax: +86 28‐6753 5588 电邮 Email: chengdu@tongshang.com 网址 Web: www.tongshang.com 北京通商（成都）律师事务所 关于海创药业股份有限公司 2025 年第二次临时股东会的 法律意见书 致：海创药业股份有限公司 根据《中华人民共和国律师法》《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》《上市公司股东会规则》等法律、 法规和规范性文件以及《海创药业股份有限公司章程》（以下简称"《公司章 程》"）的规定，北京通商（成都）律师事务所（以下简称"本所"）接受海 创药业股份有限公司（以下简称"公司"）的委托，指派律师出席公司于 2025 年 12 月 24 日召开的 ...

每经头条（nbdtoutiao）——左手"欠款"右手"豪购"！杨陵江收购"国内酒庄第一股"，1919是否重启上 市？"吹太多牛都实现了，但千亿还没实现，我很着急" （记者 王晓波） 截至发稿，海创药业市值为51亿元。 每经AI快讯，海创药业（SH 688302，收盘价：51.35元）12月24日晚间发布公告称，公司第二届第十六 次董事会会议于2025年12月24日在公司会议室以通讯表决方式召开。会议审议了《关于审议豁免本次会 议通知时限的议案》等文件。 2025年1至6月份，海创药业的营业收入构成为：药品占比99.25%，材料及研发中间体占比0.75%。 ...

证券代码：688302 证券简称：海创药业 公告编号：2025-055 全体董事对本次董事会会议议案进行了审议，经表决形成如下决议： （一）审议通过《关于审议豁免本次会议通知时限的议案》 公司董事会认为：豁免本次会议通知时限符合《公司章程》和《董事会议事规 则》的规定。 经审议，董事会同意《关于审议豁免本次会议通知时限的议案》。 海创药业股份有限公司 第二届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 海创药业股份有限公司（以下简称"公司"）第二届董事会第十六次会议于 2025年12月24日在公司会议室以通讯表决方式召开，本次会议经全体董事书面同意 已豁免提前通知时限。本次会议应到董事7名，实到董事7名，会议由董事长 YUANWEI CHEN（陈元伟）先生主持。本次会议的召集、召开、议案审议程序符合 《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公 司章程》的有关规定，会议决议合法、有效。 二、董事会会议审议情况 表决结果：同意7票，反对0票，弃 ...

Core Insights - The incidence of acute gout is rising globally, particularly among younger populations aged 18-35, who account for nearly 60% of cases, with a significantly higher male-to-female ratio [1][5] - By 2024, the global number of acute gout patients is expected to reach 45.4 million, with China contributing approximately 19.4 million cases; this number is projected to increase to 47.7 million globally and 22.2 million in China by 2025 [1][5] - The global acute gout drug market is expected to stabilize around $1.5 billion by 2025, with China's market size estimated at $0.1 billion [1][5] Industry Definition and Classification - Gout is a type of crystal arthritis caused by purine metabolism disorders or reduced uric acid excretion, primarily characterized by the deposition of monosodium urate crystals [2][3] - Treatment options are categorized into two main types: drugs for acute gout attacks and uric acid-lowering drugs [3][4] Current Industry Status - The acute gout drug market has remained stable despite rising patient numbers due to price increases leading to decreased sales volume [5] - The need for effective treatment is critical as uncontrolled acute attacks can lead to increased frequency and severity, impacting patients' quality of life [5] Industry Chain - The upstream of the acute gout drug industry includes raw materials, intermediates, and production equipment; the midstream focuses on drug R&D and production, while the downstream involves distribution channels and end patients [6] Regulatory Environment - The Chinese government has been enhancing policy guidance and regulation in the acute gout drug industry through various healthcare and drug management policies to promote healthy industry development [6] Competitive Landscape - Major competitors in the acute gout drug market include companies like Haichuang Pharmaceutical, Heng Rui Medicine, Yifang Bio, and Yipinhong, which are actively developing clinical pipelines for hyperuricemia and gout treatments [7][8] - The market is characterized by a strong demand for new, safe uric acid-lowering drugs, as existing treatments do not fully meet clinical needs [7] Development Trends - The acute gout drug industry in China is rapidly evolving, with market expansion and increasing competition driven by policy support, technological advancements, and market demand [10] - The industry is moving towards more precise, effective, and personalized treatment options, with a focus on domestic alternatives to improve patient outcomes [10]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, recommending a focus on innovative drugs and sectors with improving performance, such as medical devices and upstream segments [3][4]. Core Insights - The pharmaceutical sector experienced a decline of 1.0% this week, ranking 17th among 31 sub-industries. The overall valuation of the pharmaceutical sector stands at 29.2 times earnings, placing it 10th among the primary industries [2][4][7]. - Key events include Fosun Pharma granting exclusive global rights for its oral GLP-1 drug to Pfizer, with potential total payments reaching $2.085 billion. Additionally, Eli Lilly's GLP-1/GIP/GCGR agonist Retatrutide showed promising Phase III clinical data, achieving a weight loss of 28.7% over 68 weeks [3][14][17]. - The report highlights significant mergers and acquisitions, such as Sobi's acquisition of Arthrosi for $950 million upfront and $550 million in milestone payments, and Zhaoli Pharmaceutical's planned acquisition of a multi-trace element injection asset group for approximately RMB 356 million [3][15][22]. Market Performance - The pharmaceutical index decreased by 1.0% this week, while the Shanghai Composite Index fell by 0.3%. The overall performance of the pharmaceutical sector was ranked 17th among 31 sub-industries [2][4][6]. - The report details the performance of various sub-sectors, with notable declines in medical circulation (-4.2%), offline pharmacies (-4.3%), and blood products (-4.1%), while medical R&D outsourcing saw an increase of 3.7% [7][11]. Recent Key Events - The report discusses recent business developments, including the approval of Shanghai Pharma's new drug, and the change of control at Tailong Pharmaceutical, which will now be under Jiang Pharmaceutical Holdings [20][22]. - It also notes the IPO application of Shiyao Innovation, which was accepted with a market value of RMB 47.9 billion, focusing on health-related sectors and innovative drugs [23]. Company Valuation - The report provides a valuation table for key companies in the pharmaceutical sector, indicating projected earnings per share (EPS) and price-to-earnings (PE) ratios for 2025 to 2027. For instance, Mindray Medical is projected to have a PE of 23 in 2025, while Hengrui Medicine is expected to have a PE of 48 [29].

Core Viewpoint - The enthusiasm for insurance capital to acquire listed companies has surged, reaching 37 instances this year, marking a near 10-year high and the second highest in history, only behind 62 instances in 2015 [1][5]. Group 1: Regulatory Actions - The Hebei Securities Regulatory Bureau issued a warning letter to Great Wall Life Insurance for failing to disclose timely information regarding its acquisition of shares in Xintian Green Energy, violating the Securities Law of the People's Republic of China [3]. - Great Wall Life Insurance increased its stake in Xintian Green Energy to 5.0027% by acquiring 1 million shares, but did not halt trading upon reaching the 5% threshold, which is a regulatory requirement [3][4]. Group 2: Company Performance - Great Wall Life Insurance's insurance business revenue for the first three quarters of 2025 was 21.455 billion yuan, a decrease of 5.92% compared to 22.806 billion yuan in the same period last year [4]. - The net profit for Great Wall Life Insurance in the first three quarters of 2025 was 872 million yuan, down 70.92% from 2.972 billion yuan in the same period of 2024, with a quarterly net loss of 122 million yuan [4]. Group 3: Market Trends - The current year has seen a significant increase in insurance capital acquisitions, with a notable focus on high-quality equity investments, particularly in sectors like banking, public utilities, and environmental protection [7]. - The insurance capital's preference for high ROE and high dividend stocks indicates a strategic shift towards stable investment returns, with various insurance companies participating in the acquisition trend [7][8]. - The asset allocation of insurance funds in stocks and funds has risen to 15.5%, creating more room for acquisitions and signaling a positive outlook for the market [8].

Core Insights - The release of the 2025 National Medical Insurance Drug List and the first version of the Commercial Health Insurance Innovative Drug List has significantly benefited innovative drug companies on the Sci-Tech Innovation Board [1] - A total of 9 innovative drugs from Sci-Tech Innovation Board companies have been included in the new list, showcasing their strong capabilities [1] - The simultaneous release of the commercial insurance drug list marks a substantial breakthrough in the multi-layered payment system of "medical insurance + commercial insurance" [1] Group 1: Inclusion in Medical Insurance - Nearly 90% of innovative drugs from Sci-Tech Innovation Board companies have received medical insurance support, accelerating their value release and development [2] - Junshi Bioscience's drug, Junsida, is the only domestic PCSK9-targeted drug for statin-intolerant patients included in the new medical insurance list [2] - Haichuang Pharmaceutical's drug, Hainaan, has been approved for treating metastatic castration-resistant prostate cancer and will enhance market promotion and patient accessibility [2] Group 2: New Drug Development - New anti-tumor drugs from companies like Ailis, Yifang Biotech, and Shenzhou Cell provide precise treatment options for major diseases such as lung cancer and head and neck squamous cell carcinoma [3] - Several drugs covering endocrine, hematology, tumor support, and autoimmune treatment areas have been quickly included in the medical insurance list, demonstrating efficient drug review and approval processes [3] Group 3: Commercial Health Insurance Directory - The first version of the Commercial Health Insurance Innovative Drug List enhances the national multi-layered medical security system, with a clear division of roles between basic medical insurance and commercial insurance [4] - Innovative drugs from leading companies like BeiGene have been among the first to be included in this new directory, showcasing their clinical value [4][5] Group 4: Renewal and Market Expansion - Successful renewal negotiations confirm the exceptional value and clinical status of innovative drugs from Sci-Tech Innovation Board companies [6] - Junshi Bioscience's drug, Tuoyi, has expanded its medical insurance coverage with new indications, benefiting a broader patient population [6] Group 5: R&D Investment and Innovation Cycle - R&D investment among Sci-Tech Innovation Board companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42% [7] - The formation of a virtuous cycle of "R&D investment - innovation results - medical/commercial insurance support - market returns - reinvestment in R&D" is evident in the industry [7]

Group 1 - Haichuang Pharmaceutical increased by over 10% [1] - Frontier Biotech rose by over 8% [1] - Yuekang Pharmaceutical, Rejing Biotech, Huisheng Biotech, and Zhongsheng Pharmaceutical also experienced gains [1]